85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05515627 (ClinicalTrials.gov) | February 15, 2023 | 12/8/2022 | Atezolizumab for Idiopathic Pulmonary Fibrosis | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Atezolizumab | Cedars-Sinai Medical Center | Genentech, Inc. | Recruiting | 50 Years | 80 Years | All | 24 | Phase 1 | United States |
| 2 | JPRN-jRCTs031190084 | 05/09/2019 | 27/08/2019 | TORG1936 / AMBITIOUS study | A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study | Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia | Atezolizumab 1200mg, every 3 weeks | KATO Terufumi | IKEDA Satoshi | Complete | >= 20age old | Not applicable | Both | 38 | Phase 2 | Japan |